Switzerland· 68797001
Elzonris
A tagraxofusp product containing tagraxofuspum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Tagraxofusp is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XX67 (tagraxofusp), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Tagraxofusp · ATC L01XX67
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- tagraxofuspum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01XX67
- ATC class
- Tagraxofusp
- Defined daily dose
- 0.2 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680687970013Durchstf 1 mlCHF 16973.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for tagraxofusp.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tagraxofusp · interactions on record
82 records
- 9 severe
- 73 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tagraxofusp in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainELZONRIS 1 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONStemline Therapeutics B.V.
- United StatesElzonrisStemline Therapeutics, Inc.
- BelgiumElzonris 1 mg/mlStemline Therapeutics
- CzechiaELZONRISStemline Therapeutics B.V., Amsterdam
- FinlandELZONRISStemline Therapeutics B.V.
- IrelandELZONRIS 1 mg/mL concentrate for solution for infusionTMC Pharma (EU) Limited
- IcelandELZONRISStemline Therapeutics B.V.
- Japanタグラキソフスプ(遺伝子組換え)日本新薬
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elzonris
- Liechtenstein · Elzonris
- Norway · Elzonris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/60c626d4-fc6e-498d-bbc3-e1a7aab601b5 GET /v1/drugs/60c626d4-fc6e-498d-bbc3-e1a7aab601b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "tagraxofuspum 1 mg",
"valid_from": "2026-07-01",
"limitations": "[{\"description\":\"Die Therapie mit ELZONRIS bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nELZONRIS (Tagraxofusp) wird vergütet als Monotherapie für die Erstlinienbehandlung erwachsener Patienten mit blastischer plasmazytoider dendritischer Zellneoplasie (BPDCN).<br>\\nDie Verschreibung von ELZONRIS darf nur durch einen Facharzt der medizinischen Onkologie, Hämatologie oder Dermatologie mit Erfahrung in der Behandlung der BPDCN erfolgen.<br> \\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung ELZONRIS einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21579.01<br>\\n<br> \\n\",\"costApproval\":null,\"indication\":\"21579.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-06-01\",\"validTo\":\"2028-05-31\"}]",
"galenic_form": "Inf Konz 1 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2024-01-01",
"self_retention_pct": 10
}See everything about tagraxofusp.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.